Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Saladax Biomedical has signed an agreement with Karolinska University Hospital to supply the novel 5-fluorouracil personalized chemotherapy management reagent kits.
Subscribe to our email newsletter
The test provides oncologists with a new tool for monitoring blood level of 5-FU in cancer patients undergoing chemotherapy. This rapid test is said to be faster than currently available methods, enabling personalized dose management with the goal of minimizing toxicity and maximizing the therapeutic benefit of 5-FU treatment.
Olof Beck, laboratory director at the clinical pharmacology laboratory at Karolinska University Hospital, said: “We look forward to bringing this test to market to provide oncologists with an evidence-based tool to monitor individual patient dosing based upon their plasma 5-FU concentration level.
“As a result, physicians will be better able to manage their patients and make more confident decisions in colorectal cancer treatment.”